Institution
Istituto Tumori Bari
Recent research
- Health & MedicineOpen access
The Senescence-Malignancy Axis: An Inflammaging Perspective
The transition from physiological cellular senescence to malignancy is not an isolated event, but a gradual, systemic remodeling of the biological landscape orchestrated by the persistent state of inflammaging. As detailed in this review, senescent populations do not remain passi...
- Health & MedicineOpen access
ABSTRACT Background Homologous recombination repair (HRR) testing is increasingly relevant in prostate cancer because it identifies patients who may benefit from biomarker‐guided treatment strategies, including poly(ADP‐ribose) polymerase inhibitors (PARPi). However, real‐world i...
- Health & MedicineOpen access
Abstract Asciminib selectively targets the myristoyl pocket of ABL1, offering high specificity and a potentially improved safety profile. Its efficacy has been demonstrated in both clinical trials and real-world settings, including heavily pretreated patients and those with T315I...
- Health & MedicineOpen access
species. Because of its infiltrative growth, abscess formation, and fibrotic reaction, it may closely mimic malignant disease. We report the case of a 53-year-old woman presenting with abdominal pain and a palpable epigastric mass. Imaging showed a pelvic mass with abdominal wall...
- Health & MedicineOpen access
Abstract Dehydration is a frequent complication among rectal cancer patients after ileostomy, often resulting in hospital readmission. The Dehydration Readmission after Ileostomy Prediction (DRIP) score was used to identify patients at risk of dehydration-related readmission. The...
- Health & MedicineOpen access
Background/Objectives: H. pylori is the main preventable risk factor for gastric cancer through the development of extensive precancerous lesions, namely mucosal atrophy and intestinal metaplasia. Methods: This multicenter, nationwide study enrolled consecutive patients who under...
- Health & Medicine
Summary Background and Objectives Cemiplimab was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (cSCC). Patients and Methods We report findings from the Italian early access program cohort, comprising 134 patients treated with cemiplimab, with...